|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
norepinephrine reuptake inhibitor
|
|
gptkbp:approvedBy
|
1993
|
|
gptkbp:ATCCode
|
gptkb:N06AX16
|
|
gptkbp:availableOn
|
extended-release capsule
immediate-release tablet
|
|
gptkbp:brand
|
gptkb:Effexor_XR
gptkb:Effexor
|
|
gptkbp:CASNumber
|
93413-69-5
|
|
gptkbp:cause
|
weight loss
withdrawal symptoms
increased blood pressure
increased risk of suicidal thoughts in young people
|
|
gptkbp:chemicalFormula
|
phenylethylamine derivative
|
|
gptkbp:contraindication
|
hypersensitivity to venlafaxine
|
|
gptkbp:developedBy
|
gptkb:Wyeth
|
|
gptkbp:discoveredIn
|
1980s
|
|
gptkbp:drugClass
|
SNRI
|
|
gptkbp:eliminationHalfLife
|
5 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasActiveMetabolite
|
gptkb:desvenlafaxine
|
|
gptkbp:hasMolecularFormula
|
C17H27NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
venlafaxine
|
|
gptkbp:interactsWith
|
gptkb:MAO_inhibitors
CYP2D6 inhibitors
other serotonergic drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin and norepinephrine
weak inhibitor of dopamine reuptake
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
children
|
|
gptkbp:patentExpired
|
2008
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
sometimes adolescents
|
|
gptkbp:riskFactor
|
gptkb:discontinuation_syndrome
gptkb:serotonin_syndrome
hypertension
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
sweating
insomnia
dry mouth
sexual dysfunction
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
gptkb:panic_disorder
gptkb:social_anxiety_disorder
gptkb:major_depressive_disorder
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:Effexor
|
|
gptkbp:bfsLayer
|
6
|